ProstaLund

1 January-31 December

• Net sales reached SEK 17,4 (17,1) million
• Loss after taxes SEK -11,1 (-7,9) million
• Earnings per share were SEK -0,21 SEK (-0,17)
• Cash and equivalents were 12,3 (13,2) million
• The board proposes that no dividend be paid to the company's shareholders

Significant events during period

• Distribution agreement signed for Spain
• Distribution agreement signed for China
• Distribution agreement signed for Italy
• Results for the registry study on prostate cancer were presented at the Urology Days by one of the authors

1 October-31 December

• Net sales increased 12% to SEK 5,5 (4,9) million
• Loss after taxes SEK -3,1 (-2,2) million
• Earnings per share were SEK -0,05 SEK (-0,04)

Significant events after the end of the period

• Study on the Schelin Catheter is published
• CE-mark for the new platform Eagle obtained
• Patent that include the Schelin Catheter is approved
• Agreement with Sergelkliniken is signed
• Agrement with Carlshamns Specialist klinik is signed
• Agreement with SLG Kalmar is signed with an order value of at least SEK 2,4 million

” The network of contacts and the interest that we have created among the world's
urologists during the last six months will be very valuable going forward.”

Johan Wennerholm
CEO, ProstaLund AB (publ)

Please see attached PDF for full report.